A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

A team from UNIGE and HUG has discovered a subgroup of immune cells particularly involved in the disease, opening the way to ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams.

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...

Cognitive behavioral therapy and the mild stimulant modafinil both reduce fatigue in people with multiple sclerosis by about the same amount, finds a new study. Combining talk therapy and medication ...

New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer will benefit from five medicines that Pharmac will fund from 1 December 2025.

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

People with multiple sclerosis appear to have higher rates of thyroid problems than the general population. The link isn’t clear, but shared pathways and MS medication side effects may play a role. MS ...